

May 8, 2014  
SymBio Pharmaceuticals Limited  
Fuminori Yoshida  
Representative Director  
President and Chief Executive Officer

## **Notice Concerning Non-Operation Expense**

SymBio Pharmaceuticals Limited (“the Company”) announces that the following non-operating expense has incurred for the first three months of the fiscal period ending December 31, 2014 (from January 1, 2014 to March 31, 2014).

### 1. Details of non-operating expense

The Company recognized the foreign exchange loss of 42,076 thousand yen as a non-operating expense in the statement of operations for the first three months of the fiscal year ending December 31, 2014 (from January 1, 2014 to March 31, 2014) due to recent fluctuation of foreign exchange rates.

### 2. Future outlook

Based on the assumption of operational trends for this fiscal year, the Company determined that it would give no significant impact on the Company’s results of operations for the year; thus, no modification necessary to the financial forecast as of today.

The Company will make a prompt announcement when any modification to the financial forecast is considered necessary.

### **[Contact]**

Investor Relations

Tel: +81(0)3 5472 1125